Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 27.58% | 29.43% | -8.62% | 36.88% | 24.25% |
| Total Depreciation and Amortization | -2.28% | -13.19% | 11.56% | -5.85% | -8.70% |
| Total Amortization of Deferred Charges | -86.14% | -62.12% | 42.47% | -- | -- |
| Total Other Non-Cash Items | -94.85% | -74.29% | 140,820.00% | 106.88% | -105.81% |
| Change in Net Operating Assets | 52.87% | 133.51% | -262.91% | -124.28% | 170.92% |
| Cash from Operations | 67.10% | 68.10% | 37.27% | 6.44% | 64.95% |
| Capital Expenditure | -116.09% | 70.13% | -87.62% | 65.38% | -658.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -922.56% | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -115.07% | -- | -100.00% | -81.42% | -- |
| Cash from Investing | -55.59% | 54.94% | -95.47% | 81.52% | -1,211.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.46% | -6.02% | -0.79% | -24.26% | -12.55% |
| Issuance of Common Stock | -- | -- | -98.97% | -80.56% | 319.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24.80% | -7.93% | -34.46% | -243.48% | 223.45% |
| Foreign Exchange rate Adjustments | 158.38% | -1,682.20% | -94.97% | -45.75% | 430.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.15% | 48.19% | 18.94% | 11.73% | 62.32% |